Evidence map›Paper›PMID 33485845›Full record

ReviewExperimental eye research2021

Systemic diseases and the cornea.

Ruchi Shah, Cynthia Amador, Kati Tormanen, Sean Ghiam, Mehrnoosh Saghizadeh, Vaithi Arumugaswami, Ashok Kumar, Andrei A Kramerov, Alexander V Ljubimov

Abstract readReview
In one paragraph

Review in Experimental eye research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed.

  1. Trial
  2. Article
  3. Ferroptosis: A Novel Mechanism in Diabetic Keratopathy.Investigative ophthalmology & visual science · 2026
    Article
  4. Long-Term Tolerability and Safety of AAV5-Id3 Gene Therapy to Eyes.Translational vision science & technology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ruchi ShahEye Program, Board of Governors Regenerative Medicine Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Electronic address: Ruchi.Shah@cshs.org.
Cynthia AmadorEye Program, Board of Governors Regenerative Medicine Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Kati TormanenCenter for Neurobiology and Vaccine Development, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Sean GhiamSackler School of Medicine, New York State/American Program of Tel Aviv University, Tel Aviv, Israel.
Mehrnoosh SaghizadehEye Program, Board of Governors Regenerative Medicine Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Departments of Molecular and Medical Pharmacology, Medicine, and Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Vaithi ArumugaswamiDepartments of Molecular and Medical Pharmacology, Medicine, and Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Ashok KumarDepartment of Ophthalmology, Visual and Anatomical Sciences, Wayne State University, Detroit, MI, USA.
Andrei A KramerovEye Program, Board of Governors Regenerative Medicine Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Alexander V LjubimovEye Program, Board of Governors Regenerative Medicine Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Departments of Molecular and Medical Pharmacology, Medicine, and Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: ljubimov@cshs.org.

Funding

Mechanisms of Epithelial Alterations in Diabetic CorneaR01EY013431 · NEI · CEDARS-SINAI MEDICAL CENTER · PI Alexander V Ljubimov · 2001 to 2026
$11.3M
The Role of gK in HSV-1 Induced Corneal ScarringR01EY013615 · NEI · CEDARS-SINAI MEDICAL CENTER · PI HOMAYON GHIASI · 2002 to 2026
$7.8M
The Role of MicroRNAs in Normal and Diseased Corneal Epithelial HomeostasisR01EY025377 · NEI · CEDARS-SINAI MEDICAL CENTER · PI Mehrnoosh Saghizadeh Ghiam · 2015 to 2026
$4.3M
Role of Macrophages in control of Ocular HSVR01EY024649 · NEI · CEDARS-SINAI MEDICAL CENTER · PI HOMAYON GHIASI · 2015 to 2026
$4.1M
Therapeutic control of HSK by CD80R01EY026944 · NEI · CEDARS-SINAI MEDICAL CENTER · PI GHIASI, HOMAYON · 2016 to 2025
$3.9M
Targeting NAD metabolism to ameliorate bacterial endophthalmitisR01EY026964 · NEI · WAYNE STATE UNIVERSITY · PI Ashok Kumar · 2017 to 2026
$3.7M
Ocular HSV: Mechanism of virus reactivationR01EY029160 · NEI · CEDARS-SINAI MEDICAL CENTER · PI HOMAYON GHIASI · 2018 to 2026
$3.4M
Mechanisms of Inflammation Resolution in Bacterial EndophthalmitisR01EY027381 · NEI · WAYNE STATE UNIVERSITY · PI Ashok Kumar · 2017 to 2026
$3.3M
Regulation of Limbal Niche in Normal and Diabetic Cornea by Extracellular VesiclesR01EY029829 · NEI · CEDARS-SINAI MEDICAL CENTER · PI GHIAM, MEHRNOOSH SAGHIZADEH · 2019 to 2023
$2.6M
Wnt5a, a New Diabetic Corneal Marker Related to Wound HealingR01EY031377 · NEI · CEDARS-SINAI MEDICAL CENTER · PI LJUBIMOV, ALEXANDER V · 2020 to 2024
$2.1M
NEI NIH HHS R01 EY013431NEI NIH HHS R01 EY013615NEI NIH HHS R01 EY024649NEI NIH HHS R01 EY025377NEI NIH HHS R01 EY026944NEI NIH HHS R01 EY026964NEI NIH HHS R01 EY027381NEI NIH HHS R01 EY029160NEI NIH HHS R01 EY029829NEI NIH HHS R01 EY031377
6 · The paper itself

Abstract

There is a number of systemic diseases affecting the cornea. These include endocrine disorders (diabetes, Graves' disease, Addison's disease, hyperparathyroidism), infections with viruses (SARS-CoV-2, herpes simplex, varicella zoster, HTLV-1, Epstein-Barr virus) and bacteria (tuberculosis, syphilis and Pseudomonas aeruginosa), autoimmune and inflammatory diseases (rheumatoid arthritis, Sjögren's syndrome, lupus erythematosus, gout, atopic and vernal keratoconjunctivitis, multiple sclerosis, granulomatosis with polyangiitis, sarcoidosis, Cogan's syndrome, immunobullous diseases), corneal deposit disorders (Wilson's disease, cystinosis, Fabry disease, Meretoja's syndrome, mucopolysaccharidosis, hyperlipoproteinemia), and genetic disorders (aniridia, Ehlers-Danlos syndromes, Marfan syndrome). Corneal manifestations often provide an insight to underlying systemic diseases and can act as the first indicator of an undiagnosed systemic condition. Routine eye exams can bring attention to potentially life-threatening illnesses. In this review, we provide a fairly detailed overview of the pathologic changes in the cornea described in various systemic diseases and also discuss underlying molecular mechanisms, as well as current and emerging treatments.

Indexed as

Autoimmune DiseasesComorbidityCorneaCOVID-19HumansSARS-CoV-2Addison's diseaseAniridiaAutoimmune diseaseCorneal deposit disorderDiabetic corneaEhlers-Danlos syndromeGenetic corneal diseaseGraves' diseaseHerpesImmunobullous diseaseInflammationKeratoconjunctivitisMarfan syndromePseudomonas aeruginosaSARS-CoV-2Sjögren's syndromeSyphilisTuberculosisZoster

Identifiers

PMID33485845
PMCPMC7946758

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.